This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for relapsed/refractory multiple myeloma. This report series is based on primary research data collected at one month, three months, and one year postcommercial availability of Darzalex and Empliciti. Along with awareness and sources of familiarity, the report assesses U.S. hematological oncologists’ trial, adoption, and use of these agents, including anticipated future trends. The report provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Johnson & Johnson/Janssen’s and Bristol-Myers Squibb’s promotional efforts, and benchmarking against other agents for multiple myeloma.

Table of contents

  • Multiple Myeloma - Emerging Therapies - Darzalex/Empliciti Launch Tracking Wave 1 (US)
    • Key Findings
      • Aided Awareness of Darzalex Was High One-Month Postlaunch
      • Most Respondents Say that BMS Reps Are Very Knowledgeable About Empliciti
      • Who Is the Darzalex/Empliciti Patient?
      • Who Is the Darzalex Prescriber?
      • Who Is the Empliciti Prescriber?
      • Trends & Multiple Myeloma Market
        • Wave 1 Uptake of Darzalex and Empliciti in the Relapsed/Refractory Settings
        • Darzalex and Empliciti’s Place in the Multiple Myeloma Market
        • Expert Opinion
    • Benchmarking Darzalex Empliciti Launch Success vs. Other Recently Launched Oncology Therapies
      • Perceptual One-Month Postlaunch Metric
    • Prescriber and Nonprescriber Profiles
      • Darzalex: Differences Between Prescriber and Nonprescriber Profiles
        • Empliciti: Differences Between Prescriber and Nonprescriber Profiles
        • Darzalex Empliciti Awareness and Perceptions
          • Unaided and Aided Awareness of Darzalex Empliciti
            • Unaided Awareness of Therapies for Multiple Myeloma
            • Hematological Oncologists’ Awareness of Darzalex and Empliciti
            • Level of Familiarity
          • Familiarity with Darzalex Empliciti
            • Level of Familiarity
            • Populations for Whom Physicians Believe Darzalex Is Approved
            • Populations for Whom Physicians Believe Empliciti Is Approved
            • Physicians’ Perceived Prices of Darzalex and Emplicti per Month
          • Sources of Familiarity with Darzalex Empliciti
            • Sources of Familiarity
          • Initial Reaction to and Interest in Darzalex Empliciti
            • Darzalex Product Profile
            • Empliciti Product Profile
            • Level of Favorability
          • Impressions of Darzalex and Empliciti
            • Level of Interest
            • Level of Uniqueness
            • Other Advantages of Empliciti
            • Perceived Disadvantages
            • Other Disadvantages of Darzalex
            • Other Disadvantages of Empliciti
          • Prescriber and Nonprescriber Profiles
          • Darzalex Empliciti Trial and Use
            • Willingness to Prescribe Darzalex Empliciti
              • Level of Willingness to Prescribe
              • Current Treatment of Multiple Myeloma: Select Quotes from Qualitative Interviews
              • Darzalex and Empliciti Use: Select Quotes from Qualitative Interviews
            • Number of Patients Currently Receiving Darzalex Empliciti
              • Hematological Oncologists Prescribing Darzalex and Empliciti to Patients Outside of Clinical Trials
              • Mean Number of Darzalex- and Empliciti-Treated Patients
              • Reasons for Darzalex Discontinuation
              • Reasons for Empliciti Discontinuation
              • Withholding of Darzalex and Empliciti Dosing After an Adverse Event
              • Patient Populations Prescribed Darzalex Off-Label
              • Patient Populations Prescribed Empliciti Off-Label
              • Prescription of Drugs by Line of Therapy
              • Physician-Reported Patient Share by Line of Therapy (n = 74)
              • Impact of Darzalex on Prescribing
              • Impact of Empliciti on Prescribing
            • Reasons for Not Yet Prescribing Darzalex Empliciti
              • Main Reason for Not Prescribing Darzalex and Empliciti
              • Factors Discouraging Hematological Oncologists from Prescribing Darzalex in Approved Settings
              • Factors Discouraging Hematological Oncologists from Prescribing Empliciti in Approved Settings
            • Anticipated Darzalex Empliciti Use
              • Most Likely Therapies to Prescribe
              • Anticipated Prescribing of Darzalex and Empliciti Among Current Nonprescribers
              • Qualitative Quotes
              • Multiple Myeloma Treatments Darzalex and Empliciti Are Most Likely to Replace
            • Darzalex Empliciti Performance on Key Attributes
              • Risk/Benefit Relationship
              • Overall Level of Satisfaction
              • Satisfaction with Efficacy
              • Satisfaction with Safety and Tolerability
          • Effectiveness of Face-to-Face Detailing for Darzalex Empliciti
            • Darzalex Empliciti Sales Representative Frequency and Reach
              • Last Time of Contact with a Darzalex and Empliciti Representative
              • Time of Last Contact with Sales Representative
            • Satisfaction with Darzalex Empliciti Sales Representative
              • Sales Representative Performance
            • Darzalex Empliciti Message Recall
              • Topics Discussed with Darzalex Sales Representative
              • Education Materials Provided to Patients Prescribed Darzalex or Empliciti
              • Specific Patient Education Materials Provided for Darzalex (^n = 8)
              • Specific Patient Education Materials Provided for Empliciti (^n = 6)
          • Methodology
            • Significance Testing in This Study
          • Appendix
            • Primary Market Research Methodology
              • Practice Location
              • Distribution of Hematological Oncologists by Region
              • Years in Clinical Practice
              • Practice Type
              • Number of Multiple Myeloma Patients
              • Number of Hematological Oncologists in Practice
            • Additional Information
              • Market Background
              • Market Background: Key Agents for Relapsed/Refractory Multiple Myeloma
              • U.S. Development Milestones for Darzalex and Empliciti
              • Market News
              • Report Abbreviations
              • Objectives
              • Patient Inquiries about Darzalex in Past Month
              • Hematological Oncologist Action Based on Specific Patient Inquiries
              • Share of Patients with Requirements for Managed Care Approval
              • Influence of Managed Care Approval
              • Patient Inquiries about Empliciti in Past Month
              • Hematological Oncologist Action Based on Specific Patient Inquiries
              • Percentage of Darzalex Prescriptions Denied
              • Reasons for Denial of Darzalex Prescriptions
              • Preferred Therapy Choices for Patient with Multiple Myeloma Previously Prescribed Velcade + Dexamethasone (BD)
              • Prescribe Darzalex
              • Drivers for Starting Patient on Darzalex
              • Barriers for Starting Patient on Darzalex
              • Prescribe Empliciti + Revlimid + Dexamethasone
              • Drivers for Starting Patient on Empliciti + Revlimid + Dexamethasone
              • Barriers for Starting Patient on Empliciti + Revlimid + Dexamethasone
              • Change in Therapy Choice If Patient Received Revlimid + Dexamethasone (Rd) First Line and Disease Was Well Controlled for 24 Months
              • Preferred Therapy Choices for Patient with Multiple Myeloma Quickly Progressed to Fourth Line of Therapy
              • Prescribe Darzalex
              • Drivers for Starting Patient on Darzalex
              • Barriers for Starting Patient on Darzalex
              • Prescribe Empliciti + Revlimid + Dexamethasone
              • Drivers for Starting Patient on Empliciti + Revlimid + Dexamethasone
              • Barriers for Starting Patient on Empliciti + Revlimid + Dexamethasone
              • Percentage of Empliciti Prescriptions Denied
              • Reasons for Denial of Empliciti Prescriptions
              • Ease and Speed of Managed Care Process
              • Existence of Darzalex and Empliciti Attributes of Which Hematological Oncologists Were Unaware
              • Reasons for Prescribing Other Agents over Darzalex in the Fourth Line
              • Reasons for Prescribing Other Agents over Empliciti in the Relapsed/Refractory Setting
              • Coordination of Simultaneous Dosings for Patients Prescribed Darzalex or Empliciti to Minimize Drug Waste
              • Reasons for NOT Coordinating Darzalex Dosing (^n = 7)
              • Reasons for NOT Coordinating Empliciti Dosing (^n = 5)

        Author(s): Dana Gheorghe

        Dana Gheorghe, Ph.D., is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a Ph.D. in cellular biology and biochemistry from the University of Sheffield and a B.Sc./Honors in Molecular Biology from the University of Edinburgh.


        Related Reports

        Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

        The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed...

        View Details

        Multiple Myeloma - Epidemiology - Emerging Markets

        DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries w...

        View Details

        Multiple Myeloma - Epidemiology - Mature Markets

        DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

        View Details

        Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage

        DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient pop...

        View Details